File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Genome-wide expression analysis identifies the association between SEC14L2 and castration-resistant prostate cancer survival

TitleGenome-wide expression analysis identifies the association between SEC14L2 and castration-resistant prostate cancer survival
Authors
KeywordsCastration-resistant prostate cancer
Expression
Prognosis
Issue Date2021
Citation
Journal of Cancer, 2021, v. 12, n. 8, p. 2173-2180 How to Cite?
AbstractBackground: Mechanism of castration-resistant prostate cancer (CRPC) is still unclear. Our objective is to investigate the association between genes expression and CRPC through the genome-wide approach and functional researches. Methods: Differentially expressed genes (DEGs) between PCa and CRPC tissues were identified using expression profile obtained from Gene Expression Omnibus database (GEO). Survival analysis was performed using online database Gene Expression Profiling Interactive Analysis (GEPIA). Oncomine database was further used to explore the relationship between DEGs expression levels with clinical parameters. After in silico study, SEC14L2-knockdown CRPC cells and normal prostatic epithelial cells were used for in vitro study to verify its biological functions. Results: A total of 3 consistently changed DEGs (SEC14L2, DMD, SEL1L) were identified correlating with CRPC after cross validation in three independent datasets. Low expression of SEC14L2 was associated with poorer disease-free survival and higher Gleason score than normal/high expression of SEC14L2. SEC14L2 knockdown promoted cell proliferation, migration, invasion as well as cell cycle progression in CRPC cells (all P<0.05) while no significant effects were observed in normal prostatic epithelial cells. Conclusions: Low expression of SEC14L2 was significantly associated with CRPC, and correlated with PCa aggressiveness and poorer prognosis. SEC14L2 might be a potential biomarker or drug target for CRPC.
Persistent Identifierhttp://hdl.handle.net/10722/314408
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLiu, Shiyun-
dc.contributor.authorHuang, Da-
dc.contributor.authorHuang, Jingyi-
dc.contributor.authorYan, Jiaqi-
dc.contributor.authorChen, Tianhe-
dc.contributor.authorZhang, Ning-
dc.contributor.authorJiang, Guangliang-
dc.contributor.authorGao, Yi-
dc.contributor.authorXu, Danfeng-
dc.contributor.authorNa, Rong-
dc.date.accessioned2022-07-20T12:03:58Z-
dc.date.available2022-07-20T12:03:58Z-
dc.date.issued2021-
dc.identifier.citationJournal of Cancer, 2021, v. 12, n. 8, p. 2173-2180-
dc.identifier.urihttp://hdl.handle.net/10722/314408-
dc.description.abstractBackground: Mechanism of castration-resistant prostate cancer (CRPC) is still unclear. Our objective is to investigate the association between genes expression and CRPC through the genome-wide approach and functional researches. Methods: Differentially expressed genes (DEGs) between PCa and CRPC tissues were identified using expression profile obtained from Gene Expression Omnibus database (GEO). Survival analysis was performed using online database Gene Expression Profiling Interactive Analysis (GEPIA). Oncomine database was further used to explore the relationship between DEGs expression levels with clinical parameters. After in silico study, SEC14L2-knockdown CRPC cells and normal prostatic epithelial cells were used for in vitro study to verify its biological functions. Results: A total of 3 consistently changed DEGs (SEC14L2, DMD, SEL1L) were identified correlating with CRPC after cross validation in three independent datasets. Low expression of SEC14L2 was associated with poorer disease-free survival and higher Gleason score than normal/high expression of SEC14L2. SEC14L2 knockdown promoted cell proliferation, migration, invasion as well as cell cycle progression in CRPC cells (all P<0.05) while no significant effects were observed in normal prostatic epithelial cells. Conclusions: Low expression of SEC14L2 was significantly associated with CRPC, and correlated with PCa aggressiveness and poorer prognosis. SEC14L2 might be a potential biomarker or drug target for CRPC.-
dc.languageeng-
dc.relation.ispartofJournal of Cancer-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectCastration-resistant prostate cancer-
dc.subjectExpression-
dc.subjectPrognosis-
dc.titleGenome-wide expression analysis identifies the association between SEC14L2 and castration-resistant prostate cancer survival-
dc.typeArticle-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.7150/jca.50299-
dc.identifier.scopuseid_2-s2.0-85103595092-
dc.identifier.volume12-
dc.identifier.issue8-
dc.identifier.spage2173-
dc.identifier.epage2180-
dc.identifier.eissn1837-9664-
dc.identifier.isiWOS:000624131100002-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats